SUBSCRIBE: eNewsletter
In this slideshow, we revisit some of our most popular stories of the year: Insurers weigh in on step therapy, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis, conflicting studies were published on treatments that may (or, may not) cause deadly infections, among others.
Rheumatoid arthritis and type 2 diabetes mellitus share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes. In this slideshow, we highlight some of the similarities.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
Studies that explore the efficacy and safety of JAK inhibitors for rheumatoid arthritis are among those we selected as most noteworthy in 2019. Also, at the top of the list, a study that shows glucocorticoids, not necessarily biologics, raise the infection risk after joint replacement surgery. Learn more in this slideshow.
There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements.
In this slideshow, we review the year's most noteworthy new books in rheumatology as selected by BookAuthority.com. This is by no means a comprehensive list, but it offers a good look at the diverse selections of rheumatology books published this year.
Step therapy policies may be blocking timely access to care for rheumatology patients, finds a new report by Xcenda, an AmerisourceBergen company. The report finds that patients are more likely to be nonadherent or pay out of their own pocket for drugs. Learn more in this slideshow.
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
In this month's rheumatoid arthritis quiz, we focus on contraception, a patient's preference for tapering and the self-management of flares.
In this month's psoriatic arthritis quiz, we revisit studies presented at the American College of Rheumatology annual meeting last month. Included here is one that highlights interesting trends in prescribing practices by physicians from different specialties. Which specialty is more likely to prescribe more medications?
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
